Renal Function–Guided Valganciclovir Dosing and Ganciclovir Exposure Variability: A Population Pharmacokinetic Simulation Study
Basic & Clinical Pharmacology & Toxicology · 2026-12 · 139 (6)
DOI: 10.1111/bcpt.70329 ↗At a glance
Journal article in Basic & Clinical Pharmacology & Toxicology, published online on 2026-11-05. Written by Franck Maizaud and 6 co-authors. Institution: Department of Pharmacology, Toxicology and Pharmacovigilance, CHU Limoges, Limoges, France. Major MEDLINE topics: Valganciclovir, Antiviral Agents, Cytomegalovirus Infections, Ganciclovir. 27 references. The full text is freely available (open access, CC BY 4.0).
Abstract (original language)
Background
Ganciclovir (GCV) exposure after standard valganciclovir (VGCV) prophylaxis is highly variable. Guidelines recommend Cockcroft–Gault for renal dose adjustment. We evaluated whether Cockcroft–Gault‐based dosing achieves the target prophylactic exposure (AUC 0‐24h: 40–60 mg.h/L) and whether MDRD or CKD‐EPI alters exposure.
Methods
Using a validated population pharmacokinetic model, we simulated 10 000 adult solid organ transplant recipients. VGCV doses were assigned according to SmPC renal function categories based on Cockcroft–Gault, MDRD or CKD‐EPI. Patient reclassification, target attainment and exposure around dosing thresholds (25, 40 and 60 mL/min) were assessed.
Results
MDRD and CKD‐EPI reclassified 45.1% and 39.9% of patients, mostly downward, lowering target attainment (20.1% and 22.7% vs. 30.8% with Cockcroft–Gault). Target attainment never exceeded 40% in any category, and underexposure predominated, reaching up to 94.1% in the most impaired renal function categories. Target attainment was consistently lower just below each threshold, and the 25 and 40 mL/min thresholds were set above the renal function ranges where the corresponding regimens achieved target exposure.
Conclusions
Renal function category‐based VGCV dosing does not reliably achieve target GCV exposure. Current thresholds are poorly aligned with the exposure‐response relationship and warrant re‐examination. Alternative equations do not reduce the variability, supporting exposure‐guided approaches such as therapeutic drug monitoring and model‐informed precision dosing.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Pharmacology, Toxicology and Pharmacovigilance, CHU Limoges, Limoges, France.
- INSERM UMR-1248 "Pharmacology & Transplantation", Limoges, France.
- University Hospital Federation "Survival Optimization in Organ Transplantation" (FHU SUPORT), Limoges, France.
- Institute of Pharmacy, CHU Lille, Lille, France.
- Department of Gastroenterology, CHU Lille, Lille, France.
- METRICS Research Laboratory (ULR 2694), Lille University, Lille, France.
ORCID profiles: Franck Maizaud, Marc Labriffe, Stéphanie Belaiche, Pierre Marquet, Jean-Baptiste Woillard, Caroline Monchaud
Cite
APA
Maizaud, F., Labriffe, M., Sayadi, H., Belaiche, S., Marquet, P., Woillard, J. B., & Monchaud, C. (2026). Renal Function–Guided Valganciclovir Dosing and Ganciclovir Exposure Variability: A Population Pharmacokinetic Simulation Study. Basic & Clinical Pharmacology & Toxicology, 139(6). https://doi.org/10.1111/bcpt.70329
Vancouver
Maizaud F, Labriffe M, Sayadi H, Belaiche S, Marquet P, Woillard JB, et al. Renal Function–Guided Valganciclovir Dosing and Ganciclovir Exposure Variability: A Population Pharmacokinetic Simulation Study. Basic & Clinical Pharmacology & Toxicology. 2026;139(6). doi:10.1111/bcpt.70329
BibTeX
@article{Maizaud2026,
author = {Maizaud, Franck and Labriffe, Marc and Sayadi, Hamza and Belaiche, Stéphanie and Marquet, Pierre and Woillard, Jean-Baptiste and Monchaud, Caroline},
title = {Renal Function–Guided Valganciclovir Dosing and Ganciclovir Exposure Variability: A Population Pharmacokinetic Simulation Study},
journal = {Basic & Clinical Pharmacology & Toxicology},
year = {2026},
volume = {139},
number = {6},
doi = {10.1111/bcpt.70329}
}
EUVIMED